Bio-Rad Laboratories (BIO) as of March 31, 2026 presents a structurally complex liquidation picture dominated by two features: a massive long-term investment portfolio and a net loss driven entirely by mark-to-market losses on the Sartorius AG equity position. Under the liquidation lens, book equity of $6.85B collapses materially once haircuts are applied to the asset base. The MFFAIS CLV of -$1.36B and LLV of -$934M reflect this compression. The operating entity itself (OLV of -$163M) shows negative recovery even before considering the financial asset stack, consistent with the balance sheet structure of a capital-intensive life science manufacturer. Total assets are $9.79B, but the single largest component is LongTermInvestments at $5.31B, which includes the Sartorius stake carried at fair value. In Q1 2026, this position generated an unrealized loss of $727.7M on the equity and an $8.4M loss on the associated Euro-denominated loan receivable, producing a consolidated net loss of $527.1M on $592.1M of net sales. Under a liquidation scenario, the Sartorius position and related loan receivable (a 400M Euro loan secured by trust interests in Sartorius ordinary shares) would be subject to significant discount risk: the trust interests are not exchange-tradeable, and forced-sale execution would likely produce substantial shortfalls versus carrying value. The loan collateral adequacy is explicitly flagged as a risk in the filing. On the liability side, the $400M 3.3% Senior Notes due March 2027 have been reclassified to current (OtherLongTermDebtCurrent = $400.5M), adding to the current liability stack of $917M and meaningfully tightening near-term liquidity headroom. The $800M 3.7% Notes due 2032 remain non-current. Total operating lease liability is $174.8M (face value, non-extinguishing on windup). Deferred income tax liability of $881.8M reflects the embedded tax obligation on the Sartorius unrealized gains; this liability does not extinguish on winding up and would crystallize on asset dispositions. Goodwill of $577.1M and net intangibles of $166.8M receive zero recovery under the liquidation lens, destroying approximately $744M of book asset value. Inventory of $770.5M at 60% recovery yields approximately $462M. PP&E net of $527.5M at 50-70% yields roughly $264-369M. AR of $426.2M at 90-95% yields approximately $383-405M. Cash and short-term investments of approximately $1.56B (cash $507M plus short-term investments $1.06B) recover near par. The asymmetry between haircut assets and face-value liabilities produces deeply negative equity recovery, consistent with the MFFAIS CLV output. No restructuring charges were separately tagged in XBRL this quarter, though the MD&A references lower restructuring costs as a partial gross margin driver, suggesting ongoing but declining restructuring spend not independently tagged.
▼ Community Notes